HOME >> BIOLOGY >> NEWS
Rockefeller University Researchers Hunt For Type 2 Diabetes Susceptibility Genes

The Rockefeller University is looking for people with type 2 diabetes to participate in a study aimed at determining the genetic causes of early- and late-onset forms of the disease. The study is part of the research program of the university's Starr Center for Human Genetics.

"We hope that by identifying genes that cause type 2 diabetes we can develop better diagnostic tools and improved drug therapies, and in the long term, a possible way of preventing this disease," says Assistant Professor Markus Stoffel, M.D., Ph.D., principal investigator of the study and head of the Laboratory of Metabolic Diseases. Stoffel, the university's Robert and Harriet Heilbrunn Professor, is an Irma Hirschl Scholar and a Pew Scholar. He received the Career Development Award in 1997 from the American Diabetes Association.

Genes constitute some of the most important risk factors for type 2 diabetes, although environment also plays a role in the disease. Most common forms of diabetes are polygenic, meaning that more than one gene is involved in the disease, making it difficult to identify the genes responsible. By enrolling a large number of participants, the study investigators hope to identify as many type 2 diabetes susceptibility genes as possible.

Type 2 diabetes is caused by ineffective insulin secretion or improper insulin action on target tissues such as muscle, leading to impaired glucose uptake from the blood and increased levels of blood glucose. Type 2 diabetes is the most common form of diabetes, accounting for 90 to 95 percent of cases. In about 5 percent of cases, inheritance follows a classic autosomal dominant pattern?anyone in a family who has one copy of the defective gene is likely to develop hyperglycemia or increased levels of blood glucose?and is characterized by an early age of onset.. Known as maturity onset-diabetes of the young (MODY), this form of diabetes usually develops before age 25. S
'"/>

Contact: Joseph Bonner
runews@rockvax.rockefeller.edu
212-327-7900
Rockefeller University
3-Apr-1998


Page: 1 2 3

Related biology news :

1. Rockefeller University scientists take on controversial vibration theory of smell
2. By the year 2050, human population could add 2.6 billion people, reports Rockefeller scientist
3. White House awards National Medal of Science to Rockefeller Universitys James Darnell
4. Lasker Award honors Rockefeller University biochemist for pioneering studies of gene activation
5. Rockefeller scientists identify natural proteins that push stem cells to produce hair, not skin
6. Rockefeller, Weill Cornell researchers find link between estrogen, brain structure changes
7. Rockefeller researchers provide the first functional evidence for mammalian pheromone receptors
8. Another transmembrane protein structure solved by Rockefeller scientists
9. Rockefeller researchers identify defense system in plants
10. Rockefeller University Centennial Symposium to explore biology of drug abuse and addiction
11. Rockefeller University researchers discover immune-cell mechanism that boosts therapeutic antibody potency

Post Your Comments:
(Date:3/11/2015)... , March 11, 2015   The ... its platform to scientifically measure and harness music ... to real-time biometrics and objective measurements of physiology, ... music at scale in large populations. It is ... technologists and clinicians perform rigorous studies and accelerate ...
(Date:3/10/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ... biometric authentication company focused on the growing mobile ... has been named the "Number One Best Tech ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a web ... and lifestyle that have a unique function or design.  ...
(Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
(Date:3/30/2015)... , March 30, 2015 CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... Drug Administration (CFDA) has approved the Company,s application to ... clear cell carcinoma (OCCC) patients for its proprietary drug ...
(Date:3/30/2015)... GERMANTOWN, Md. , March 30, 2015  /PRNewswire/ ... a leader in synthetic biology, and Merck Serono, ... Germany , today announced an exclusive ... commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. ... to develop innovative therapies that modulate the immune ...
(Date:3/30/2015)... Washington, USA (PRWEB) March 29, 2015 ... and the United States and plenary talks by four ... SPIE Optics + Optoelectronics next month in ... technical presentations in 17 conferences alongside a two-day exhibition. ... and photonics , the event will run 13-16 April ...
(Date:3/30/2015)... 2015  Naldemedine, an investigational peripherally acting mu-opioid ... Co., Ltd., met its primary and secondary endpoints ... the treatment of opioid-induced constipation (OIC) in adult ... Study results showed that naldemedine (0.2 mg tablet ... of spontaneous bowel movement (SBM) compared with placebo ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: